KPW
NBIX icon

Kore Private Wealth’s Neurocrine Biosciences NBIX Stock Holding History

Kore Private Wealth’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-288
Closed -$35K – 795
2020
Q2 		$35K Hold
288
– – 0.01% 538
2020
Q1 		$25K Hold
288
– – 0.01% 553
2019
Q4 		$31K Buy
+288
New +$30.2K 0.01% 556
2019
Q2 		– Sell
-326
Closed -$29K – 592
2019
Q1 		$29K Buy
326
+250
+329% +$20.9K 0.01% 461
2018
Q4 		$5K Buy
+76
New +$7.28K ﹤0.01% 681

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Kore Private Wealth's NBIX Position: Q3 2020 in Review

Kore Private Wealth sold out of Neurocrine Biosciences (NBIX) in Q3 2020, closing a stake of 288 shares — an estimated $35K sold.

Kore Private Wealth first reported a position in NBIX in Q4 2018 and held it in 5 quarters. The position peaked at $35K in Q2 2020. 418 funds tracked by Wall St. Rank hold NBIX as of Q3 2020.

  • Kore Private Wealth reported no remaining Neurocrine Biosciences position as of Q3 2020 after selling out during the quarter.
  • Kore Private Wealth sold 288 Neurocrine Biosciences shares in Q3 2020, an estimated $35K.
  • Kore Private Wealth first reported a position in Neurocrine Biosciences in Q4 2018 and held it in 5 quarters.
  • Kore Private Wealth's Neurocrine Biosciences position peaked at $35K in Q2 2020.
  • 418 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2020.

Based on Kore Private Wealth's 13F filing for Q3 2020, filed 13 Nov 2020.